Yutrepia Capsule
Product Images NDC 72964-013

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Yutrepia (NDC 72964-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Liquidia Technologies, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure of treprostinil, the active ingredient in Yutrepia. The diagram depicts the molecular arrangement including functional groups and stereochemistry relevant to the compound's identity as a respiratory inhalation drug.*

FDA Label Image

Figure 1 (Image 02)

A line graph illustrating the percentage of patients with greater six-minute walk distance (6MWD) change from baseline comparing Treprostinil inhalation solution versus placebo. The graph shows a solid line for Treprostinil (N=115) and a dashed line for placebo (N=120), with percent annotations at 52% and 32% highlighting differences in patient responses at specific 6MWD changes.*

FDA Label Image

Figure 2 (Image 03)

A forest plot chart comparing placebo and Treprostinil Inhalation Solution across multiple subgroups. It includes sample sizes by age quartile, gender, geographic region, etiology, baseline six-minute walk distance quartile, and background therapy. The chart displays relative effect sizes with confidence intervals for each subgroup along a horizontal axis ranging approximately from -20 to 100.*

FDA Label Image

Figure 3 (Image 04)

A horizontal error bar plot showing placebo-corrected median treatment effects at various study visits (Week 4, Week 8, Week 12, Week 16, and Week 15 Trough). Each point represents an H-L estimate with accompanying 95% confidence intervals indicating variability around the median effects.*

FDA Label Image

Figure 4 (Image 05)

A forest plot comparing treatment effects between Tyvaso and placebo across various patient subgroups. The chart shows estimated differences with 95% confidence intervals and p-values for categories including age groups, sex, baseline 6-minute walk distance, pulmonary hypertension etiology, baseline pulmonary vascular resistance, and maximum study drug dose. The horizontal axis ranges from placebo better to Tyvaso better.*

FDA Label Image

Figure 5 (Image 06)

A Kaplan-Meier survival curve graph depicting the percentage of patients without an event over 16 weeks comparing two groups: Tyvaso (solid blue line) and Placebo (dashed red line). The x-axis represents time in weeks, and the y-axis shows the percent of patients without events. Below the graph is a table listing the number of patients at risk for each group at various time points.*

FDA Label Image

Figure A (IFU)

An instructional diagram showing parts of an inhaler device and a blister card. The inhaler is labeled with its cover, mouthpiece, puncture buttons, and base. The blister card displays capsules and a desiccant tab. Below is an illustration of a cleaning brush for the inhaler device.*

FDA Label Image

Figure B (IFU)

An instructional illustration showing a hand placing a blister pack of capsules into an open box, next to a blue inhaler device on a surface. This image likely demonstrates storage or packaging handling related to the respiratory inhalation dosage form of Yutrepia (treprostinil).*

FDA Label Image

Figure C (IFU)

A data table titled 'Capsules Needed' showing the combinations of capsule colors and doses required to achieve various total doses of treprostinil inhalation capsules. It lists colors by dose: yellow (26.5 mcg), green (53 mcg), blue (79.5 mcg), and purple (106 mcg), and details capsule combinations to reach doses ranging from 26.5 mcg to 212 mcg.*

FDA Label Image

Figure D (IFU)

An instructional illustration showing a person inhaling from a blue inhaler device. The image includes a close-up of the nose and the inhaler tip, alongside a blister pack containing six capsule-shaped units, indicating how to use the capsule with the inhaler device.*

FDA Label Image

Figure E (IFU)

An instructional illustration depicting a person holding a blister pack of capsules near their nose, indicating inhalation usage. The image includes text showing an example of an expiration date format labeled as EXP: MMM/YYYY.*

FDA Label Image

Figure F (IFU)

Illustration showing hands demonstrating how to use a respiratory inhalation device by pulling upward on the blue cap, likely part of the Yutrepia inhalation system for administering treprostinil capsules.*

FDA Label Image

Figure G (IFU)

An instructional diagram showing a hand holding a component of the Yutrepia inhalation capsule device. The first part highlights an arrow pointing to a specific part of the device. The second part shows the hand twisting or lifting a device component, with a directional arrow indicating the motion.*

FDA Label Image

Figure H (IFU)

An instructional illustration showing a blister pack containing capsules with integrated desiccant tabs. The image highlights a single capsule in the pack and demonstrates how one capsule unit should be popped out for use.*

FDA Label Image

Figure I (IFU)

Illustration showing how to peel back a foil blister pack to access the capsule inside. The image includes an arrow indicating the direction to peel and a label pointing to the peel area.*

FDA Label Image

Figure J (IFU)

An instructional illustration showing a hand placing a capsule into the capsule chamber of an inhalation device. The image highlights the capsule chamber and the capsule being inserted as part of device preparation, associated with the Yutrepia treprostinil inhalation capsule product.*

FDA Label Image

Figure K (IFU)

An instructional illustration labeled Figure K showing a hand holding a small device component under a larger apparatus with a downward arrow indicating how to attach or insert the component. This likely relates to the use or assembly of the Yutrepia respiratory inhalation capsule device.*

FDA Label Image

Figure L (IFU)

An instructional illustration showing hands holding a capsule device labeled Yutrepia, with arrows indicating to press and release puncture buttons on the device for respiratory inhalation use. The text instructs users to "Press and Release Puncture Buttons."*

FDA Label Image

Figure M (IFU)

Illustration showing a person holding and preparing to use a respiratory inhalation device, presumably for administering Yutrepia (treprostinil) capsules. The image depicts the inhaler positioned near the mouth, illustrating the proper use technique.*

FDA Label Image

Figure N (IFU)

An instructional illustration showing a side view of a person's mouth with the word 'Exhale' and arrows indicating exhalation. Below, the person is holding an inhalation device upright with one hand, demonstrating proper use posture.*

FDA Label Image

Figure O (IFU)

An instructional illustration depicting a person using an inhalation device. The person is shown holding the inhaler up to their mouth and inhaling, with arrows indicating airflow direction inward, labeled 'Inhale.' This image demonstrates correct inhalation technique for a respiratory medication.*

FDA Label Image

Figure P (IFU)

An instructional illustration showing a side profile of a person holding their breath, accompanied by text reading "Hold Breath" and a clock graphic indicating a duration of 5 seconds. This figure is likely part of inhalation usage instructions for Yutrepia capsules.*

FDA Label Image

Figure Q (IFU)

An instructional diagram illustrating the inhalation process for Yutrepia capsules. It shows a person exhaling, then inhaling the medication through a device, followed by holding the nosepiece and inhaling again, emphasizing proper use of the inhalation device for administration.*

FDA Label Image

Figure R (IFU)

An instructional illustration showing a hand holding a capsule inhaler device while another hand lifts a cylindrical capsule from the device. The image demonstrates how to remove or insert the capsule into the inhaler for respiratory administration.*

FDA Label Image

Figure S (IFU)

An instructional illustration showing a hand holding a capsule above a trash can labeled 'TRASH', demonstrating disposal of the capsule by dropping it into the trash.*

FDA Label Image

When Dosing With More Than One Capsule... (Image 26)

A dosing instruction panel for Yutrepia capsules indicating steps to follow when dosing with more than one capsule for doses of 132.5 mcg and larger. It advises users to repeat certain steps for each additional capsule and notes that the order of dosing capsules does not matter regardless of strength.*

FDA Label Image

Figure T (IFU)

An instructional illustration showing how to open a Yutrepia inhalation capsule device by lifting the top cover with fingers. The image demonstrates proper handling of the capsule inhaler before use.*

FDA Label Image

Figure U (IFU)

An instructional illustration showing a person holding a blue inhaler device with one hand while pressing down with the thumb of the other hand to activate it. The image is labeled 'Figure U' and includes a downward-pointing arrow indicating the motion to press the inhaler.*

FDA Label Image

Figure V (IFU)

An instructional illustration showing a hand wiping the mouthpiece of a device, labeled 'Wipe Mouthpiece.' This image is likely intended to demonstrate proper cleaning or maintenance of a respiratory inhalation device.*

FDA Label Image

Figure W (IFU)

An instructional illustration showing a hand holding a Yutrepia inhalation device with the brush chamber removed. The brush chamber is labeled and is being detached or cleaned, demonstrating part of device maintenance or preparation for use.*

FDA Label Image

Figure X (IFU)

An instructional illustration showing a hand discarding a blue, white, and gray capsule inhaler into a trash can. A calendar displaying a sequence of marked days is shown nearby, suggesting a timed or scheduled disposal process for the capsule inhaler device.*

FDA Label Image

Principal Display Panel (26.5 mcg Carton)

Yutrepia 26.5 mcg inhalation powder capsules for oral inhalation only, manufactured by Liquidia Technologies, Inc. The label indicates each capsule contains 26.5 mcg of treprostinil. Packaging includes 28 capsules in 7 foil blister cards with 4 capsules each, a dry powder inhaler, single-use cleaning brushes, and instructions for use. The label advises storage at 68°F to 77°F (20°C to 25°C) and cautions not to swallow capsules.*

FDA Label Image

Principal Display Panel (53 mcg Carton)

Packaging label for Yutrepia (treprostinil) 53 mcg capsules, inhalation powder for oral inhalation only. The label shows dosage strength and usage instructions, distributed by Liquidia Technologies, Inc. It includes contents such as 28 capsules in blister cards, a dry powder inhaler, and cleaning brushes, with cautions to not swallow capsules and storage conditions.*

FDA Label Image

Principal Display Panel (79.5 mcg Carton)

Yutrepia 79.5 mcg capsules label for treprostinil inhalation powder. The label shows the product name, active ingredient, dosage form, strength per capsule, and states it is for oral inhalation only. It includes storage instructions and contents: 28 capsules, 1 dry powder inhaler, 7 single-use cleaning brushes, and instructions for use. Distributed by Liquidia Technologies, Inc.*

FDA Label Image

Principal Display Panel (106 mcg Carton)

Yutrepia 106 mcg per capsule inhalation powder for oral inhalation only, distributed by Liquidia Technologies, Inc. The label includes dosage instructions and storage conditions, and packaging information showing 28 capsules in blister cards, one dry powder inhaler, single-use cleaning brushes, and instructions for use. The product contains treprostinil as the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.